ADC Targeted Talks
Unlocking the Future of Targeted Therapies
Welcome to Debiopharm ADC Targeted Talks, where we delve into the latest advancements and insights in Antibody-Drug Conjugates (ADCs). Join us as our experts share their knowledge and experiences, paving the way for innovative targeted therapies.
Where does Debiopharm stand in the field of ADCs?
Bertrand Ducrey, CEO
Introducting the Series, Bertrand Ducrey provides an overview of our ADC pipeline, core capabilities, highlighting how we leverage our unique business model to advance ADC research.
Why is Acute Myeloid Leukemia (AML) a suitable target for ADCs?
Lisa Ivanschitz, Associate Principal Scientist
Lisa explores the potential of Debio 1562M, our most advanced ADC program to address the high unmet medical need of Acute Myeloid Leukemia (AML).
How do ADCs differ from conventional cancer treatments?
Leo Marx, Medicinal Chemist and Bioconjugates Manager
Léo describes the unique potential of ADCs, highlighting their “Trojan horse” effect, the critical role of the linker in the ADC structure and the expected benefits for cancer patients.
How are ADCs transforming the landscape of cancer treatment?
Sophie Brachet, Head of early commercial and access and Marianna Muller, Senior Medical Director Oncology
Sophie and Marianna describe the benefits of ADCs and their capacity as targeted therapy to increase the therapeutic window and target both current and new cancer markers. They explain how ADCs are emerging as a true game-changer and revolutionizing cancer treatment. They also highlight Debiopharm’s strategy and commitment to delivering our current ADCs to patients.
How do we accelerate ADC Development?
Nicolas Favre, Chief Business Officer
Nicolas, shares his insights on the reasons ADCs have become a leading topic of interest in oncology and how our unique ‘trifecta’ approach (target selection, payload choice and proprietary Multilink™ technology), combined with our collaborative business model, accelerates ADC development from concept to commercialization.
Why is ADC development such an interesting challenge?
Olivier Cochet, Head of Pharmaceutical Development
Olivier explores the challenging landscape of ADC development; from the specialized skills needed to essential manufacturing requirements. Drawing on years of hands-on experience, he shares key insights and lessons learned from navigating the evolving ADC ecosystem.
Developing fit-for-purpose antibody drug conjugates through a tailored “trifecta” approach
Projects in development in the areas of oncology, infectious disease, and conjugation technologies
